Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study

A legfontosabb adatok

Ki végzi
Nationwide Children's Hospital
Hol
Aurora, Columbus, Detroit, Los Angeles, Philadelphia, Pittsburgh, San Francisco és Washington D.C. (Egyesült Államok)Mind a 8 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
75 fő vett részt
Kezdés
2018. dec. 5.
Befejezés
2023. dec. 5.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • GM-CSF
A regiszteradat frissítve
2026. május 5.

Ki vehet részt

Életkor
Legfeljebb 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • >= 40 weeks gestational age to <18 years; AND
  • Onset of >=2 new organ dysfunctions (compared to pre-sepsis baseline) as measured by the Proulx criteria; AND
  • Documented or suspected infection as the MODS inciting event

Ki nem vehet részt

  • Renal replacement therapy at the time of screening; OR
  • Previous enrollment in the GRACE study
  • Active (or planned within 7 days) immunosuppressive treatment for oncologic, transplant, or rheumatologic disease; OR
  • Known primary immunodeficiency disorder; OR
  • Diagnosis of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia;OR
  • Known allergy to GM-CSF; OR
  • Documented hyperferritinemia (serum ferritin >= 500 ng/ml) during current sepsis event; OR
  • Unable to collect a cumulative total of 20.5 mL of blood for this study due to research blood draw limits; OR
  • Limitation of care order at the time of screening; OR
  • Patients at high risk for brain death; OR
  • Contraindication to SQ injection (ECMO); OR
  • Burns where >5% of the total body surface area is affected; OR
  • On ECMO or anticipated to require ECMO; OR
  • Known pregnancy; OR
  • Inability to collect and ship sample for immune testing on MODS Day 2; OR

Helyszínek itt: Egyesült Államok

  • Children's Hospital of ColoradoAurora, Egyesült Államok
  • Nationwide Children's HospitalColumbus, Egyesült Államok
  • Children's Hospital of MichiganDetroit, Egyesült Államok
  • UCLA Mattel Children's HospitalLos Angeles, Egyesült Államok
  • Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
  • Children's Hospital of PittsburghPittsburgh, Egyesült Államok
  • Benioff Children's Hospital/UCSFSan Francisco, Egyesült Államok
  • Children's National Medical CenterWashington D.C., Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS. Those children who demonstrate immunoparalysis (TNF-alpha response <200 pg/ml) will receive a 7-day course of GM-CSF at a dose of 125 or 250 mcg/m2/day by either the intravenous (IV) or subcutaneous (SQ) route.

A teljes eredeti leírásKevesebb

The goal of the study is to establish the dose and route of delivery that results in resolution of immunoparalysis (TNF-alpha response >=200 pg/ml) by the morning after the 3rd scheduled dose with persistent resolution of immunoparalysis on the morning after the 7th scheduled dose. Resolution of immunoparalysis in 8 out of the first 10 subjects in a study treatment arm represents a successful dose and route. The goal of this study will be achieved through the following Specific Aims:

Specific Aim 1. Establish the immunologic efficacy of GM-CSF administered by the IV and SQ routes in children with immunoparalysis in the setting of sepsis-induced MODS.

Specific Aim 2. Estimate the pharmacokinetic parameters by the IV and SQ GM-CSF administered in pediatric sepsis-induced MODS.

Specific Aim 3. Demonstrate the feasibility of screening, enrollment, drug delivery, and sample collection for a multi-center immunostimulation trial in children with sepsis-induced MODS.

A vizsgálat 4 csoportja

  • IV GM-CSF 125 mcg/m2/doseA vizsgált kezelés

    Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.

    Kezelés: GM-CSF

  • SQ GM-CSF 125 mcg/m2/doseA vizsgált kezelés

    Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.

    Kezelés: GM-CSF

  • IV GM-CSF 250 mcg/m2/doseA vizsgált kezelés

    If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.

    Kezelés: GM-CSF

  • SQ GM-CSF 250 mcg/m2/doseA vizsgált kezelés

    If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.

    Kezelés: GM-CSF

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS (GRACE)
A regiszteradat frissítve
2026. május 5.